Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

Potent synergy, activity and patient tolerance observed in Genotype 1 patients support development of Omega DUROS(R) continuous delivery therapy

WASHINGTON, May 21, 2007 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced the presentation of final results from a Phase 2 study comparing the combination of injectable omega interferon and ribavirin to omega interferon alone in treatment-naive patients with genotype 1 chronic hepatitis C. The results demonstrate that omega interferon in combination with ribavirin is well tolerated and shows robust antiviral activity that is comparable to published data on the use of alpha interferon plus ribavirin in similar patient populations. The 72-week sustained viral response (SVR) data are being presented today at the Digestive Disease Week Conference in Washington, DC by Bruce R. Bacon, MD, Professor of Internal Medicine, Saint Louis University Medical Center, St. Louis, Missouri.

This Phase 2 study of daily subcutaneous omega interferon injections provides Intarcia with safety and clinical response data to support development of omega interferon delivered by continuous release from the DUROS(R) device.

"The safety and SVR rates achieved in this phase 2 study are encouraging in that they indicate that the combination of omega interferon and ribavirin may produce response rates which are similar to those achieved with alpha interferon and ribavirin in patients with HCV genotype-1," said Dr. Bacon. "The positive results of this study allow us to proceed with the evaluation of continuous delivery of omega interferon delivered with the DUROS device. A trial evaluating dose response of the Omega DUROS device is expected to begin in the near future."

The Phase 2 trial compared the safety and antiviral response of omega interferon alone with omega interferon in combination with ribavirin in 102 interferon-na
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lbvqqr/global_ultrasound ) ... Ultrasound Equipment Market 2015-2019" report to their ... Ultrasound Equipment market to grow at a CAGR ... Ultrasound equipment are used to examine organs using ... by cardiologists, radiologists, surgeons, obstetricians, and many other ...
(Date:3/3/2015)... 2015  Cyberonics, Inc. (NASDAQ: CYBX ), ... and management of epilepsy, today announced it will participate ... 11, 2015, in Miami . ... Executive Officer, will speak at 1:05 PM Eastern Time.  ... format, and no formal materials will be presented.  A ...
(Date:3/3/2015)... BETHESDA, Md. , March 3, 2015 /PRNewswire/-- ViaCyte, Inc., ... cell-derived islet replacement therapy for the treatment of diabetes ... Eugene Brandon , Director of Strategic Relations and ... summit showcases the latest in type 1 diabetes management ... are as follows: , , , Title:   ...
Breaking Medicine Technology:Global Ultrasound Equipment Market 2015-2019: Rise in Number of MI Diagnostic Procedures with GE Healthcare, Phillips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2ViaCyte to Present at JDRF TypeOneNation Research Summit 2
... , April 26, 2010 Thanks to promising,commercial debut of ... Technologies service offer (fully,integrated and automated patient/product tracking and supply chain) IMPLANET,S.A. ... ). , , , ... IMPLANET is proud to welcome a reference new institutional investor,CM-CIC Private ...
... April 26 Sirion Therapeutics, Inc., a privately ... gel) 0.15% is now commercially available.  Zirgan™, which was approved ... 2009 , is a topical ophthalmic antiviral indicated for the ... , , ...
Cached Medicine Technology:IMPLANET Raises Additional EUR 8 Million (USD 11 Million) to Fuel Deployment 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3
(Date:3/3/2015)... York (PRWEB) March 03, 2015 ... used to market the atypical antipsychotic medication continue ... According to court documents, the South Carolina Supreme ... that Johnson & Johnson’s Janssen Pharmaceuticals unit had ... risks. However, while the Court’s February 25th decision ...
(Date:3/3/2015)... March 03, 2015 Findings could lead ... at UC Davis have developed and characterized a molecule ... causing them to self-destruct. This novel mechanism was found ... a usually fatal type of brain cancer – and ... , The article, to be published in the April ...
(Date:3/3/2015)... Today the Brain Injury Association of America ... snow, water, and motorcycle helmets, announced a partnership agreement ... kicks off with Nutcase donating $2 from each helmet ... BIAA during the month of March in recognition of ... the nation in observing Brain Injury Awareness Month by ...
(Date:3/3/2015)... US Air Purifiers LLC , an Illinois based ... to announce that all Rabbit brand air purifiers are back ... west coast port strikes. This news comes just in time, ... The port strikes, which have caused significant supply ... growth by as much as 1%, have hindered the restocking ...
(Date:3/3/2015)... York, NY (PRWEB) March 03, 2015 ... that allege a metal-on-metal version of the artificial ... debilitating complications continue to move forward in the ... Northern District of Texas. According to the most ... on March 2, 2015, 7,350 Pinnacle hip replacement ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4Health News:Brain Injury Association of America Partners with Nutcase Helmets to Raise Awareness About Brain Injury 2Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 2Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 4
... China, May 15 /PRNewswire-Asia-FirstCall/ --, - Third Quarter 2009 Revenue ... Increased 48.8% to $1.9 Million with EPS of $0.10, - ... Income Increased 29.2% to $5.7 Million with EPS ... March 31, 2009, - Cash Flow from Operations Increased 150.6% ...
... Conference Call Today at 11am ET - SOMERSET, N.J., May ... ), a national provider of healthcare and administrative staffing services, ... March 31, 2009. TeamStaff,s operating revenues for the three months ... $16.1 million in the comparable quarter last year. The decrease ...
... Operating Income Exceeds $1 Million; Recurring Revenues ... MillionDENVER, May 15 Global Med Technologies(R), ... Bulletin Board: GLOB), an international healthcare information ... tenth consecutive quarter of revenue growth for ...
... (NORD) Recognizes BioMarin,s Efforts to Expand Treatment Options for ... Inc. (Nasdaq: BMRN ) announced today that ... National Organization for Rare Disorders (NORD), an organization dedicated ... The award was presented on May 14 at NORD,s ...
... could someday help control anxiety, experts say, , , FRIDAY, May ... and anxiety isn,t something associated with heights, a job interview ... chronic state of worry and tension that affects twice as ... reason, slowly eroding their quality of life. , But a ...
... Mouse study shows CMV raises risk of hypertension, hardening of ... viral infection that most adults harbor could be a cause ... with cytomegalovirus (CMV) were more likely to develop not only ... called atherosclerosis, according to a report in the May 15 ...
Cached Medicine News:Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results 2Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results 5Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results 6Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results 7Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results 8Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results 9Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results 10Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2009 Financial Results 11Health News:TeamStaff Reports Second Quarter Results 2Health News:TeamStaff Reports Second Quarter Results 3Health News:TeamStaff Reports Second Quarter Results 4Health News:TeamStaff Reports Second Quarter Results 5Health News:TeamStaff Reports Second Quarter Results 6Health News:TeamStaff Reports Second Quarter Results 7Health News:TeamStaff Reports Second Quarter Results 8Health News:TeamStaff Reports Second Quarter Results 9Health News:TeamStaff Reports Second Quarter Results 10Health News:TeamStaff Reports Second Quarter Results 11Health News:TeamStaff Reports Second Quarter Results 12Health News:TeamStaff Reports Second Quarter Results 13Health News:TeamStaff Reports Second Quarter Results 14Health News:TeamStaff Reports Second Quarter Results 15Health News:Global Med Technologies(R), Inc. Reports Profitability, Record Operating Income and 10th Consecutive Quarter of Record Revenue Growth 2Health News:Global Med Technologies(R), Inc. Reports Profitability, Record Operating Income and 10th Consecutive Quarter of Record Revenue Growth 3Health News:Global Med Technologies(R), Inc. Reports Profitability, Record Operating Income and 10th Consecutive Quarter of Record Revenue Growth 4Health News:Global Med Technologies(R), Inc. Reports Profitability, Record Operating Income and 10th Consecutive Quarter of Record Revenue Growth 5Health News:Global Med Technologies(R), Inc. Reports Profitability, Record Operating Income and 10th Consecutive Quarter of Record Revenue Growth 6Health News:BioMarin Receives 2009 Corporate Award for the Development of Kuvan 2Health News:BioMarin Receives 2009 Corporate Award for the Development of Kuvan 3Health News:BioMarin Receives 2009 Corporate Award for the Development of Kuvan 4Health News:Fear Response May Stem From Protein in Brain 2Health News:Viral Infection Might Trigger High Blood Pressure 2Health News:Viral Infection Might Trigger High Blood Pressure 3
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Thermometer for Round Water Bath...
... laboratory system for pH and temperature measurements. ... when used with a temperature probe (ATC) ... easy one and two-point calibration with Auto-Find ... 1.68, 4.00, 7.00, 10.01 and 12.45) and ...
... high-end microplate reader with outstanding sensitivity and ... Fluorescence Intensity - FRET , Fluorescence Polarization ... , Luminescence , , , ... reader with fastest read times. The ultimate ...
Medicine Products: